// App-Quantinova.ai

3 : Are two too many when it comes to the treatment of anal canal cancer with concurrent radiation and mitomycin C?

Researchers

Presenter

  • Zainab Al Habsi

Principal Investigators

  • Aswin George Abraham

  • Mustafa Al Balushi

  • Gabriella Tankel

  • Karen E. Mulder

  • Heather Warkentin

  • Dan E. Schiller

  • Keith Tankel

  • Nawaid Usmani

  • Diane Severin

  • Kim Paulson

  • Hatim Karachiwala

  • Clarence K. W. Wong

  • Tirath Nijjar

  • Kurian Joseph

Medical Centers

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • University of Oxford, Oxford, United Kingdom

  • University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada

  • University of Alberta, Edmonton, AB, Canada

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Division of Experimental Oncology, Cross Cancer Institute, Department of Oncology, University of Alberta, Edmonton, AB, Canada

  • Division of Experimental Oncology, Cross Cancer Institute, Edmonton, AB, Canada

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • NICU, Royal Alexandra Hospital, Edmonton, AB, Canada

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • mitomycin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved